CN1112926C - 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物 - Google Patents

含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物

Info

Publication number
CN1112926C
CN1112926C CN98805686A CN98805686A CN1112926C CN 1112926 C CN1112926 C CN 1112926C CN 98805686 A CN98805686 A CN 98805686A CN 98805686 A CN98805686 A CN 98805686A CN 1112926 C CN1112926 C CN 1112926C
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compositions
compound
chemical compound
acceptable form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98805686A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259050A (zh
Inventor
J·帕特尔
H·洛斯
R·普里斯
J·R·格拉尼特
P·N·雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of CN1259050A publication Critical patent/CN1259050A/zh
Application granted granted Critical
Publication of CN1112926C publication Critical patent/CN1112926C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN98805686A 1997-06-05 1998-06-02 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物 Expired - Lifetime CN1112926C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
GB9711683.4 1997-06-18
GB9712851.6 1997-06-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN02149972A Division CN1430959A (zh) 1997-06-05 2002-11-05 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物

Publications (2)

Publication Number Publication Date
CN1259050A CN1259050A (zh) 2000-07-05
CN1112926C true CN1112926C (zh) 2003-07-02

Family

ID=26311662

Family Applications (3)

Application Number Title Priority Date Filing Date
CN98805686A Expired - Lifetime CN1112926C (zh) 1997-06-05 1998-06-02 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物
CNA2003101199090A Pending CN1526391A (zh) 1997-06-05 1998-06-02 含有5-［4-［2-(n-甲基-n-2-吡啶基)氨基)乙氧基］苄基］噻唑烷-2，4-二酮的组合物
CN02149972A Pending CN1430959A (zh) 1997-06-05 2002-11-05 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2003101199090A Pending CN1526391A (zh) 1997-06-05 1998-06-02 含有5-［4-［2-(n-甲基-n-2-吡啶基)氨基)乙氧基］苄基］噻唑烷-2，4-二酮的组合物
CN02149972A Pending CN1430959A (zh) 1997-06-05 2002-11-05 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物

Country Status (29)

Country Link
EP (1) EP0998284A1 (fr)
JP (1) JP2001521553A (fr)
KR (1) KR20010013410A (fr)
CN (3) CN1112926C (fr)
AP (1) AP1214A (fr)
AR (2) AR015120A1 (fr)
AU (1) AU8215098A (fr)
BG (1) BG104048A (fr)
BR (1) BR9810405A (fr)
CA (2) CA2292629C (fr)
CO (1) CO4940400A1 (fr)
DZ (1) DZ2510A1 (fr)
EA (1) EA002384B1 (fr)
GB (1) GB9711683D0 (fr)
HU (1) HUP0004070A3 (fr)
ID (1) ID24264A (fr)
IL (1) IL133074A0 (fr)
MX (1) MXPA99011322A (fr)
NO (2) NO995938L (fr)
NZ (2) NZ523725A (fr)
OA (1) OA11306A (fr)
PE (1) PE78899A1 (fr)
PL (1) PL337201A1 (fr)
SK (1) SK164899A3 (fr)
TR (2) TR200002790T2 (fr)
TW (1) TW570797B (fr)
UY (1) UY25032A1 (fr)
WO (1) WO1998055122A1 (fr)
ZA (2) ZA9811572B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
PL351684A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
AU765498B2 (en) 1999-04-23 2003-09-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (fr) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Composés hétécycliques bicycliques utilisés en tant que modulateurs des ror-gamma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (fr) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Derives substitues de la thiazolidenedione

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
JPH09512249A (ja) * 1994-02-10 1997-12-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 腎臓疾患を治療するためのインスリンセンシタイザーの使用
CN1192683A (zh) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
WO1997018811A1 (fr) * 1995-11-17 1997-05-29 Warner-Lambert Company Procede de traitement de dystrophie myotonique
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
PL331148A1 (en) * 1996-07-12 1999-06-21 Smithkline Beecham Plc Novel method of treating the leptin immunity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (fr) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Derives substitues de la thiazolidenedione

Also Published As

Publication number Publication date
CO4940400A1 (es) 2000-07-24
TW570797B (en) 2004-01-11
AR008198A1 (es) 1999-12-29
DZ2510A1 (fr) 2003-01-25
AP9901696A0 (en) 1999-12-31
TR199902963T2 (xx) 2000-02-21
KR20010013410A (fr) 2001-02-26
NZ513922A (en) 2001-09-28
CN1526391A (zh) 2004-09-08
GB9711683D0 (en) 1997-08-06
CA2292629C (fr) 2004-01-06
ZA984826B (en) 1999-08-03
WO1998055122A1 (fr) 1998-12-10
CA2292629A1 (fr) 1998-12-10
NO995938L (no) 2000-02-02
SK164899A3 (en) 2000-11-07
NO995938D0 (no) 1999-12-03
BG104048A (bg) 2000-07-31
HUP0004070A3 (en) 2002-03-28
CA2333352A1 (fr) 1998-12-10
TR200002790T2 (tr) 2001-11-21
MXPA99011322A (es) 2004-12-02
NZ523725A (en) 2004-09-24
BR9810405A (pt) 2000-08-29
ZA9811572B (en) 1999-07-22
CN1430959A (zh) 2003-07-23
EP0998284A1 (fr) 2000-05-10
ID24264A (id) 2000-07-13
AU8215098A (en) 1998-12-21
PE78899A1 (es) 1999-10-22
NO20040738L (no) 2000-02-02
OA11306A (en) 2003-10-22
IL133074A0 (en) 2001-03-19
PL337201A1 (en) 2000-08-14
AR015120A1 (es) 2001-04-18
CN1259050A (zh) 2000-07-05
JP2001521553A (ja) 2001-11-06
HUP0004070A2 (hu) 2002-02-28
AP1214A (en) 2003-10-08
EA199901116A1 (ru) 2000-06-26
UY25032A1 (es) 1998-11-26
EA002384B1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
CN1429551A (zh) 用噻唑烷二酮和二甲双胍治疗糖尿病
CN1227004C (zh) 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
CN1210258C (zh) 格列本脲组合物
CN1443068A (zh) 用于治疗糖尿病的二肽基肽酶iv抑制剂和其它抗糖尿病药剂的组合用药物
HK1046277A1 (en) Benzamide formulation with histone deacetylase inhibitor activity
CN1133431C (zh) 用罗西格列酮和胰岛素治疗糖尿病
CN1430959A (zh) 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物
CN101056658A (zh) 具有改善生物利用度的口服制剂
CN1285831A (zh) 取代的噻唑烷二酮衍生物,其制备过程及其药学用途
CN101052380A (zh) 双层片剂
CN1281453A (zh) 作为药物的5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮马来酸盐的水合物
CN1264303A (zh) 用噻唑烷二酮、胰岛素促分泌剂和双胍治疗糖尿病
CZ20002205A3 (cs) Hydrát soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidin-2,4-dionu s kyselinou maleinovou
CN1168451C (zh) 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
CN1274282A (zh) 用噻唑烷二酮和α－葡糖苷酶抑制剂治疗糖尿病
CN1263467A (zh) 用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病
CN1505512A (zh) 包含托塞米变型ⅱ的稳定药物制剂
CN1264302A (zh) 用噻唑烷二酮和磺酰脲治疗糖尿病
CN100341495C (zh) 格列本脲固体分散体、口服组合物及其制备方法
CN1278684C (zh) 马来酸左旋氨氯地平的制备方法和应用及含其药物组合物
CN1239501C (zh) 噻唑烷二酮衍生物以及其作为抗糖尿病药物的应用
CN1443186A (zh) 用于糖尿病治疗的噻唑烷二酮盐
JP5102849B2 (ja) Ｎ−ヒドロキシ−４−｛５−［４−（５−イソプロピル−２−メチル−１，３−チアゾール−４−イル）フェノキシ］ペントキシ｝ベンズアミジン２エタンスルホン酸塩、その製造方法およびそれを含む薬学組成物
CN1458930A (zh) 噻唑烷二酮衍生物的酒石酸盐
CN1446090A (zh) 含有二甲双胍和5－苯氧基烷基－2,4－噻唑烷二酮类衍生物的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
AV01 Patent right actively abandoned
AV01 Patent right actively abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned